Angioedema Newswire

Comprehensive Real-Time News Feed for Angioedema.

Results 1 - 13 of 13 in Angioedema

  1. Angioedema - The Skin Disorder That WeltsRead the original story w/Photo

    Wednesday Dec 17 | Natural Holistic Health

    Angioedema is a skin condition that involves swelling in both the tissue and mucous membranes. It occurs in much the same way as hives except not on the skin surface.

    Comment?

  2. First Angioedema Treatment Center Opens at UC San Diego Health SystemRead the original story w/Photo

    Sunday Nov 30 | San Diego NewsCape

    UC San Diego Health System in partnership with the U.S. Hereditary Angioedema Association , a non-profit patient advocacy organization, has opened the nation's first dedicated center for diagnosing and treating diverse forms of swelling, known collectively as angioedema. The U.S. HAEA Angioedema Center at UC San Diego Health System will serve as an international referral center for people with all types of angioedema and will work closely with basic science laboratories at UC San Diego School of Medicine to better understand the condition and develop new treatments.

    Comment?

  3. First Angioedema Treatment Center Opens at UC San Diego Health SystemRead the original story w/Photo

    Monday Nov 24 | Patch.com

    Angioedema is a swelling that is similar to hives, but the swelling is under the skin instead of on the surface. UC San Diego Health System in partnership with the U.S. Hereditary Angioedema Association , a non-profit patient advocacy organization, has opened the nation's first dedicated center for diagnosing and treating diverse forms of swelling, known collectively as angioedema.

    Comment?

  4. UC San Diego Health System opens nation's first angioedema treatment centerRead the original story w/Photo

    Monday Nov 24 | Medical News

    UC San Diego Health System in partnership with the U.S. Hereditary Angioedema Association , a non-profit patient advocacy organization, has opened the nation's first dedicated center for diagnosing and treating diverse forms of swelling, known collectively as angioedema. The U.S. HAEA Angioedema Center at UC San Diego Health System will serve as an international referral center for people with all types of angioedema and will work closely with basic science laboratories at UC San Diego School of Medicine to better understand the condition and develop new treatments.

    Comment?

  5. First Angioedema Treatment Center Opens at UC San Diego Health SystemRead the original story

    Monday Nov 24 | Newswise

    UC San Diego Health System in partnership with the U.S. Hereditary Angioedema Association , a non-profit patient advocacy organization, has opened the nation's first dedicated center for diagnosing and treating diverse forms of swelling, known collectively as angioedema. The U.S. HAEA Angioedema Center at UC San Diego Health System will serve as an international referral center for people with all types of angioedema and will work closely with basic science laboratories at UC San Diego School of Medicine to better understand the condition and develop new treatments.

    Comment?

  6. Global angioedema market: Latest market analysis presentedRead the original story w/Photo

    Sep 12, 2014 | PR-inside.com

    This report provides elemental information and data relating to the clinical trials on Angioedema. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

    Comment?

  7. FDA Approves 2 New Indications For Epaned??, The First And Only...Read the original story w/Photo

    Sep 8, 2014 | BioSpace

    ... to decrease the rate of development of overt heart failure and reduce hospitalization for heart failure. : Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx, including some fatal reactions, have been reported in patients ...

    Comment?

  8. Spark Therapeutics Appoints Industry Leaders Lars Ekman and Vin Milano to Board of DirectorsRead the original story

    Jun 25, 2014 | Hispanic Business

    ... the lead product was Cinryze, approved and commercially available in the U.S. for the prevention of hereditary angioedema attacks and in for both the treatment and prevention of hereditary angioedema attacks, a rare disease. Vin joined the company ...

    Comment?

  9. Stocks with implied volatility below IV index mean; ZQK HSHRead the original story

    May 27, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  10. Stocks with implied volatility below IV index mean; ZQK HSHRead the original story w/Photo

    May 23, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  11. Durata Therapeutics says data from DISCOVER subject of NEJM articleRead the original story

    Jun 4, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  12. Dyax announces dosing of first subject in DX-2930 Phase 1b TrialRead the original story

    May 27, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?

  13. BioCryst data has favorable read through for Dyax, says JefferiesRead the original story

    May 27, 2014 | Theflyonthewall.com

    ... $1.81, or 27.42%, to $8.41 after another drug company, BioCryst (BCRX), reported positive data on its inherited angioedema treatment. In a note to investors earlier today, research firm Jefferies wrote that BioCryst's data bodes well for Dyax's own ...

    Comment?